MYH7
Myosin-7
As of the edition of 20 October 2026, MYH7 (myosin-7, UniProt P12883) has 4 drugs tested at it and 5 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P12883
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 46
- Disease areas
- Heart and blood vessels; Inherited and neonatal; Bones, joints and muscles; Infections; Lungs and airways; Nervous system
- Registered trials of its drugs
- 77
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Mavacamten | Marketed | Phase 4 | Ends 2036 |
| Omecamtiv mecarbil | Active | Phase 3 | none listed |
| Aficamten | Marketed | Phase 4 | Ends 2039 |
| Danicamtiv | Active | Phase 3 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 2 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Cytokinetics | Route B |
The other 4 companies at MYH7
In the product5 companies in all; 4 are not named here, and no score is.
See the 5 companies at MYH7, ranked, with the facts behind eachRequest access. Nothing is shown until you do.